Bioethics, healthcare policy, and related issues.
Ruth Faden’s group at the Phoebe R. Berman Institute has been highlighting the issue of the possible effects of research on stem cell transplantation in non-human primate models. If stem cells are to be used - as is often proposed - to counter neurodegenerative diseases like Parkinson Syndrome or senile dementia, research on the safety and efficacy of neural-stem-cell transplantation will have to be done first. It makes obvious sense that this research would have to be done in non-human models that are neurologically closest to humans, which would mean non-human primates - the dangers of attempting such therapy in humans on a completely untried basis are prohibitive. But the closeness of these animals’ neural systems to the human brain raises fears that transplanting human cells into them, or creating human/primate chimeras in utero, would result in monkeys or apes with altered cognitive capacities - perhaps (as Glen McGee tags them) “Really, Really, Smart Monkeys”, or non-human primates with human-like mental and emotional patterns. This raises qualms even within the less-queasy bioethical community. Faden is attempting to get ahead of the problem before the monkeys get pissed off and form a union.
Susan Okie, MD, has a good overview article in last week’s NEJM, reviewing the current state of regulations, ethics guidelines, and national and international research projects regarding embryonic stem cells and somatic-cell nuclear transfer research. It is not too detailed, but highlights the tensions resulting from competing pressures in the field.
[Hat tip: Phoebe Berman Inst.]
